TICKERNERD
Menu
KROSKROSHealthcare · Biotechnology

KROS Stock Forecast: Keros Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$10
−5.25% on the day

The 8 Wall Street analysts covering Keros Therapeutics, Inc. hold a median 12-month price target of $19 — +88.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$200.3M
Ticker Nerd rank
68 / 100
Median analyst target
$19
Analysts covering
8
Total return, dividends reinvested
1W
−9.4%
1M
−4.4%
YTD
−50.4%
1Y
−30.0%
From 52W high
−53.8%
From 52W low
+1.9%
$10
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KROS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Keros Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
96
Quality
88
Accruals
81
Revisions
73
Volatility
70
Size
68
Momentum
21
Value
21
Growth
9

Issuance (96): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (9): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KROS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KROS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Oct 25Jan 26Apr 26Jul 26KROSHigh $25Median $19Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
4 Buy4 Hold0 Sell
Low $16Median $19High $25

The green dot is the last close — the median target sits +88.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
4 Aug 2026Leerink PartnersMaintainsOutperform$30 → $23
4 Aug 2026Wells FargoMaintainsOverweight$20 → $18
5 Mar 2026Wells FargoMaintainsOverweight$23 → $20
5 Mar 2026Wells FargoMaintainsOverweight—
28 Nov 2025B of A SecuritiesMaintainsNeutral—
12 Nov 2025OppenheimerReiteratesOutperform—
11 Nov 2025Wells FargoMaintainsOverweight—
6 Nov 2025WedbushMaintainsNeutral—
8 Aug 2025HC Wainwright & Co.MaintainsBuy—
10 June 2025B of A SecuritiesDowngradeNeutral—
30 May 2025WedbushReiteratesNeutral—
12 May 2025ScotiabankMaintainsSector Outperform—
8 May 2025HC Wainwright & Co.MaintainsBuy—
9 Apr 2025Truist SecuritiesMaintainsBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025WedbushReiteratesNeutral—
27 Feb 2025HC Wainwright & Co.MaintainsBuy—
27 Feb 2025Wells FargoMaintainsOverweight—
21 Jan 2025Cantor FitzgeraldDowngradeNeutral—
17 Jan 2025GuggenheimReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KROS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KROS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

Keros Therapeutics, Inc. (KROS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.6×

Cheaper than 67% of US stocks

Price / sales
13.3×

Cheaper than 12% of US stocks

Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
0.4×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−655.8%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−17.2%

Higher than 32% of US stocks

Return on assets
−11.8%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KROS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KROSKeros Therapeutics, Inc.$200.3M
68
VYGRVoyager Therapeutics, Inc.$194.9M
74
DTILPrecision BioSciences, Inc.$205.1M
70
PEPGPepGen Inc.$205.5M
43
VOGXVogenx, Inc.$205.5M
1
ABOSAcumen Pharmaceuticals, Inc.$192.8M
42
KRROKorro Bio, Inc.$191.5M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Keros Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KROS news & analysis

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Zacks Investment Research · 4 Aug 2026neutral

Keros Therapeutics reported a wider second-quarter loss as revenues fell to zero, missing earnings expectations. The company's cash runway extends into H1 2028, with rinvatercept pipeline milestones keeping attention on future growth.

Why it matters — A KROS watcher would care because the company's cash position and rinvatercept pipeline progress are central to how the company can fund and deliver future growth after quarterly revenue fell to zero.

Keros Therapeutics Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 3 Aug 2026neutral

Keros Therapeutics, a clinical-stage biopharmaceutical company, provided a business update and reported its financial results for the quarter ended June 30, 2026. The announcement was made in a press release issued on August 3, 2026.

Why it matters — This quarterly financial report and business update provides KROS watchers with the company's latest operational and financial status for the period.

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

GlobeNewsWire · 30 July 2026positive

Keros Therapeutics announced it will receive a $20 million development milestone payment from partner Takeda under their elritercept license agreement, triggered by the dosing of the first patient in the Phase 3 ELRiSE MDS clinical trial comparing elritercept versus epoetin alfa for anemia due to myelodysplastic syndromes.

Why it matters — The milestone payment and Phase 3 trial initiation signal continued progress in Keros's lead product candidate elritercept under its partnership with Takeda.

New Strong Sell Stocks for July 30th

Zacks Investment Research · 30 July 2026negative

Keros Therapeutics (KROS) has been added to the Zacks Rank #5 (Strong Sell) List as of July 30, 2026, according to Zacks Investment Research.

Why it matters — A Zacks Rank #5 (Strong Sell) designation signals that analysts expect the stock to underperform in the near term, which may influence investor sentiment and trading activity.

FAQ

Frequently asked questions about KROS stock

What is the KROS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Keros Therapeutics, Inc. have a median 12-month price target of $19, with estimates ranging from $16 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KROS stock a buy right now?

Of the 8 analysts covering Keros Therapeutics, Inc., 4 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Keros Therapeutics, Inc. 68 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KROS?

As at 15 Aug 2026, Keros Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (96 of 100).

Will KROS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +88.1% from the last close, and Ticker Nerd's factor model ranks Keros Therapeutics, Inc. 68 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KROS stock forecast for 2030?

No analyst covering Keros Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KROS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $25 over the next 12 months.

How has KROS stock performed over the past year?

Keros Therapeutics, Inc. returned -30.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Keros Therapeutics, Inc. do?

Keros Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of groundbreaking treatments for hematological and musculoskeletal disorders.

What is the latest news on KROS?

The most recent item we track (Zacks Investment Research, 4 Aug 2026): "KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus". Keros Therapeutics reported a wider second-quarter loss as revenues fell to zero, missing earnings expectations. The company's cash runway extends into H1 2028, with rinvatercept pipeline milestones keeping attention on future growth.

Company

About Keros Therapeutics, Inc.

Keros Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of groundbreaking treatments for hematological and musculoskeletal disorders. The company's primary aim is to address unmet medical needs by advancing innovative therapies that target the transforming growth factor-beta (TGF-beta) family of proteins. These proteins play a critical role in the regulation of cellular growth and development, making them pivotal in treating a variety of severe diseases. Keros Therapeutics is deeply involved in research and development, with a strong pipeline of drug candidates aimed at conditions such as anemia and other blood-related disorders, as well as muscle diseases that impact patient mobility. By targeting these specific biological pathways, Keros is contributing significantly to the biopharmaceutical industry’s efforts in developing more effective and personalized medicine. The company's operations are an important part of the healthcare sector, striving to deliver breakthroughs that can enhance the quality of life for patients worldwide.

CEO Dr. Jasbir S. Seehra Ph.D. · 92 employees · United States · https://www.kerostx.com